Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3487-3494

  Holli, Kaija ^a   Valavaara, Ritva ^a   Blanco, Guillermo ^a   Kataja, Vesa ^a   Hietanen, Päivi ^a   Flander, Martti ^a   Pukkala, Eero ^a   Joensuu, Heikki ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKORRHEA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034667858     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3487     Document Type: Article

References (48)

1. Use of tamoxifen for breast cancer: Twenty-eight years later
2. Receptors
3. Endocrine therapy of metastatic breast cancer
4. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
5. Meeting highlights: International consensus panel on the treatment of primary breast cancer
6. Tamoxifen for early breast cancer: An overview of the randomized trials
7. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
8. Five years of tamoxifen - Or more?
9. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
10. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: The Scottish Cancer Trials Breast Group
11. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women
12. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital: Tamoxifen randomised chemoprevention trial
13. The prevention of breast cancer
14. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
15. A new triphenylethylene compound, FC-1157a: II. Antitumor effects
16. Agonistic and antagonistic effects of antiestrogens in different target organs
17. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women
18. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat
19. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer: Phase II study
20. Treatment of advanced breast cancer with 20 mg toremifene: A phase II study - Preliminary communication
21. First line therapy with high dose toremifene for advanced breast cancer
22. High dose toremifene vs tamoxifen in postmenopausal advanced breast cancer
23. Multicentric Phase II Trial of Efficacy and Tolerance of Toremifene (FC-1157a) in Patients with Hormonally Pretreated Advanced Breast Cancer
24. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer: A comparative study by a double blind method with tamoxifen
25. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
26. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomised double blind - The 'Nordic' phase III study
27. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
28. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
29. Statistical Tables for the Design of Clinical Trials
30. Endocrine pharmacology of antiestrogens as antitumor agents
31. Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women
32. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor
33. Prospects for antiestrogen chemoprevention of breast cancer
34. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
35. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
36. Effects of tamoxifen on spinal bone density in women with breast cancer
37. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
38. Tamoxifen and thromboembolism
39. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III
40. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
41. Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group
42. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer
43. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
44. Risk of endometrial cancer after tamoxifen treatment of breast cancer
45. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radio-therapy
46. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients
47. Present and future projects of the International Breast Cancer Study Group